• Phare
  • Validé par KD/KO

Anticorps Monoclonal anti-Cytokeratin 19

Cytokeratin 19 Monoclonal Antibody for WB, IHC, IHC-Autostainer, IF-P, IF-Fro, FC (Intra), Indirect ELISA

Hôte / Isotype

Mouse / IgG2b

Réactivité testée

Humain, porc, rat, souris

Applications

WB, IHC, IHC-Autostainer, IF-P, IF-Fro, FC (Intra), Indirect ELISA

Conjugaison

Non conjugué

CloneNo.

3G1E4

N° de cat : 60187-1-PBS

Synonymes

CK 19, CK19, KRT19, 3G1E4, CK-19



Informations sur le produit

60187-1-PBS cible Cytokeratin 19 dans les applications de WB, IHC, IHC-Autostainer, IF-P, IF-Fro, FC (Intra), Indirect ELISA et montre une réactivité avec des échantillons Humain, porc, rat, souris

Réactivité Humain, porc, rat, souris
Hôte / Isotype Mouse / IgG2b
Clonalité Monoclonal
Type Anticorps
Immunogène Cytokeratin 19 Protéine recombinante Ag7407
Nom complet keratin 19
Masse moléculaire calculée 44 kDa
Poids moléculaire observé 48 kDa
Numéro d’acquisition GenBankBC002539
Symbole du gène Cytokeratin 19
Identification du gène (NCBI) 3880
Conjugaison Non conjugué
Forme Liquide
Méthode de purification Purification par protéine A
Tampon de stockage PBS only
Conditions de stockageStore at -80°C. 20ul contiennent 0,1% de BSA.

Informations générales

Cytokeratin 19 (CK19 or KRT19) is a type I (acidic) cytokeratin. It is an intermediate filament protein providing structural rigidity and multipurpose scaffolds in epithelial cells. CK19 is often overexpressed in various cancers (e.g., hepatocellular carcinoma [HCC], pancreatic adenocarcinoma, lung cancer) and serves as a biomarker for hepatic progenitor cells (HPCs) associated with poor prognosis in HCC patients . Additionally, CK19 expression is common in pancreatic and gastrointestinal adenocarcinomasand has been studied as a potential diagnostic and prognostic marker for pancreatic neuroendocrine tumors (PNETs), where positive CK19 expression correlates with poor prognosis. Serum CK19 fragments (e.g., CYFRA 21-1, CK19-2G2) have been investigated as tumor markers for lung and breast cancer, with preoperative levels associated with metastasis and survival.

{{ptg:RelatedPrimaryAntibodies}}